52 related articles for article (PubMed ID: 11920641)
21. The predictive value of p53, p53R2, and p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma.
Okumura H; Natsugoe S; Matsumoto M; Mataki Y; Takatori H; Ishigami S; Takao S; Aikou T
Br J Cancer; 2005 Jan; 92(2):284-9. PubMed ID: 15655547
[TBL] [Abstract][Full Text] [Related]
22. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage.
Tanaka H; Arakawa H; Yamaguchi T; Shiraishi K; Fukuda S; Matsui K; Takei Y; Nakamura Y
Nature; 2000 Mar; 404(6773):42-9. PubMed ID: 10716435
[TBL] [Abstract][Full Text] [Related]
23. Disruption of the p53-p53r2 DNA repair system in ulcerative colitis contributes to colon tumorigenesis.
Yoshida T; Haga S; Numata Y; Yamashita K; Mikami T; Ogawa T; Ohkusa T; Okayasu I
Int J Cancer; 2006 Mar; 118(6):1395-403. PubMed ID: 16206288
[TBL] [Abstract][Full Text] [Related]
24. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53.
Zhou B; Liu X; Mo X; Xue L; Darwish D; Qiu W; Shih J; Hwu EB; Luh F; Yen Y
Cancer Res; 2003 Oct; 63(20):6583-94. PubMed ID: 14583450
[TBL] [Abstract][Full Text] [Related]
25. Expression of p53R2, newly p53 target in oral normal epithelium, epithelial dysplasia and squamous cell carcinoma.
Yanamoto S; Kawasaki G; Yoshitomi I; Mizuno A
Cancer Lett; 2003 Feb; 190(2):233-43. PubMed ID: 12565178
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of the p53R2 ribonucleotide reductase subunit by nitric oxide.
Guittet O; Tebbi A; Cottet MH; Vésin F; Lepoivre M
Nitric Oxide; 2008 Sep; 19(2):84-94. PubMed ID: 18474260
[TBL] [Abstract][Full Text] [Related]
27. Expression and mutation analyses of P53R2, a newly identified p53 target for DNA repair in human gastric carcinoma.
Byun DS; Chae KS; Ryu BK; Lee MG; Chi SG
Int J Cancer; 2002 Apr; 98(5):718-23. PubMed ID: 11920641
[TBL] [Abstract][Full Text] [Related]
28. The roles of p53R2 in cancer progression based on the new function of mutant p53 and cytoplasmic p21.
Yousefi B; Rahmati M; Ahmadi Y
Life Sci; 2014 Mar; 99(1-2):14-7. PubMed ID: 24486301
[TBL] [Abstract][Full Text] [Related]
29. Novel regulators and molecular mechanisms of p53R2 and its disease relevance.
Cho EC; Yen Y
Biochimie; 2016 Apr; 123():81-4. PubMed ID: 26796884
[TBL] [Abstract][Full Text] [Related]
30. The role of iron in cell cycle progression and the proliferation of neoplastic cells.
Le NT; Richardson DR
Biochim Biophys Acta; 2002 Oct; 1603(1):31-46. PubMed ID: 12242109
[TBL] [Abstract][Full Text] [Related]
31. Molecular characteristics of eight gastric cancer cell lines established in Japan.
Yokozaki H
Pathol Int; 2000 Oct; 50(10):767-77. PubMed ID: 11107048
[TBL] [Abstract][Full Text] [Related]
32. Molecular diagnosis of gastric cancer: present and future.
Yasui W; Oue N; Kuniyasu H; Ito R; Tahara E; Yokozaki H
Gastric Cancer; 2001; 4(3):113-21. PubMed ID: 11760076
[TBL] [Abstract][Full Text] [Related]
33. p53 mRNA Metabolism Links with the DNA Damage Response.
Vadivel Gnanasundram S; Bonczek O; Wang L; Chen S; Fahraeus R
Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573428
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
